#1 Clinical Trials Search in Europe

Allogeneic Crispr/Cas9-Mediated Genetically Modified Car T Cells Targeting Cd19 Antigen

This article discusses the ongoing clinical trials of a groundbreaking cancer treatment using Allogeneic CRISPR/Cas9-Mediated Genetically Modified CAR T Cells Targeting CD19 Antigen. This innovative therapy is being studied for its potential in treating various blood cancers and solid tumors. The trials aim to evaluate the long-term safety and effectiveness of this cutting-edge cellular therapy, offering hope for patients with difficult-to-treat malignancies.

Table of Contents

What is CRISPR CAR T-Cell Therapy?

CRISPR CAR T-cell therapy is an innovative treatment approach that combines two cutting-edge technologies in cancer treatment: CRISPR gene editing and CAR (Chimeric Antigen Receptor) T-cell therapy. This treatment is being studied for its potential to fight various types of cancer, including blood cancers and solid tumors[1].

In this therapy, T-cells (a type of immune cell) are taken from a donor (allogeneic means from someone other than the patient). These cells are then genetically modified using CRISPR/Cas9 technology to create special receptors on their surface called CARs. These CARs are designed to recognize and target a specific protein (in this case, CD19) found on cancer cells[1].

Target Conditions

The CRISPR CAR T-cell therapy being studied is aimed at treating two broad categories of cancer[1]:

  • Hematologic Malignancies: These are cancers that affect the blood, bone marrow, and lymph nodes. Examples include leukemia, lymphoma, and multiple myeloma.
  • Solid Malignancies: These are cancers that form solid tumors in various parts of the body, such as the lungs, breast, or colon.

Study Objectives

The main goal of this long-term follow-up study is to evaluate the safety and effectiveness of CRISPR CAR cellular therapy in patients with blood cancers and solid tumors over an extended period (up to 15 years)[1]. The study has two primary objectives:

  1. Long-term Safety: To assess any potential long-term side effects or complications that may arise from the treatment.
  2. Long-term Efficacy: To determine how well the treatment continues to work over time in controlling or eliminating cancer.

Eligibility Criteria

To participate in this long-term follow-up study, patients must meet the following criteria[1]:

  • Be able to understand and comply with the study procedures
  • Voluntarily sign an informed consent document
  • Have previously received CRISPR CAR cellular therapy

Importantly, there are no specific exclusion criteria mentioned for this study, which suggests that it aims to include a wide range of patients who have undergone this treatment[1].

Study Endpoints

The study will measure several outcomes to assess the therapy’s long-term effects[1]:

  1. Primary Endpoint: The occurrence of side effects, including:
    • Serious adverse events related to the CRISPR CAR cellular therapy
    • Adverse events of special interest
  2. Secondary Endpoints:
    • Overall survival: How long patients live after receiving the treatment
    • Duration of remission/response: How long the cancer remains controlled or undetectable after treatment

Drug Information

The specific drug being studied in this trial is called CTX110[1]. Here are some key details about this treatment:

  • Full Name: Allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting CD19 antigen
  • Form: Dispersion for infusion (a liquid form that is given directly into the bloodstream)
  • Administration Route: Intravenous (through a vein)
  • Manufacturer: CRISPR Therapeutics AG

This therapy is considered a cell therapy, which means it uses living cells as a treatment. In this case, the cells are T-cells that have been genetically modified to target cancer cells more effectively[1].

Aspect Details
Study Type Long-term follow-up, observational
Duration Up to 15 years
Target Conditions Hematologic Malignancies and Solid Tumors
Primary Objective Evaluate long-term safety of CRISPR CAR cellular therapy
Secondary Objective Assess long-term efficacy of the therapy
Key Endpoints Incidence of adverse events, overall survival, duration of remission/response
Inclusion Criteria Patients who have received CRISPR CAR cellular therapy
Exclusion Criteria None specified
Treatment Administration Intravenous infusion

FAQ

  • What is Allogeneic CRISPR/Cas9-Mediated Genetically Modified CAR T Cell therapy? This therapy uses immune cells (T cells) from donors that are genetically modified using CRISPR/Cas9 technology. These cells are engineered to target a specific protein called CD19, which is found on some cancer cells. The modified cells are then given to patients to help fight their cancer.
  • What types of cancers are being studied with this therapy? The clinical trials are focusing on both hematologic malignancies (blood cancers) and solid tumors. This broad approach aims to explore the therapy's potential in treating various types of cancer.
  • How long will patients be followed in these clinical trials? Patients will be followed for up to 15 years after receiving the therapy. This long-term follow-up is crucial to assess the safety and effectiveness of the treatment over time.
  • What are the main objectives of these clinical trials? The primary objective is to evaluate the long-term safety of the CRISPR CAR cellular therapy. Secondary objectives include assessing its long-term effectiveness in treating blood cancers and solid tumors.
  • What are some of the key outcomes being measured in these trials? The trials will monitor the incidence of adverse events, including serious events related to the therapy. They will also track overall survival rates and the duration of remission or response to the treatment.

Ongoing Clinical Trials on Allogeneic Crispr/Cas9-Mediated Genetically Modified Car T Cells Targeting Cd19 Antigen

  • Long-term Safety Study of CRISPR CAR T Cell Therapy for Patients with Blood and Solid Cancers

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Allogeneic: Refers to cells or tissues that are taken from a genetically different donor of the same species. In this context, it means the CAR T cells come from a donor, not the patient themselves.
  • CRISPR/Cas9: A gene-editing technology that allows scientists to make precise changes to DNA. In this therapy, it's used to modify T cells to better target cancer cells.
  • CAR T Cells: Chimeric Antigen Receptor T cells. These are T cells (a type of immune cell) that have been genetically modified to better recognize and attack specific cancer cells.
  • CD19 Antigen: A protein found on the surface of certain types of immune cells, including some cancer cells. It's the target for this specific CAR T cell therapy.
  • Hematologic Malignancy: Cancers that affect blood, bone marrow, and lymph nodes. Examples include leukemia and lymphoma.
  • Solid Malignancy: Cancers that form solid tumors in organs or tissues, such as breast cancer or lung cancer.
  • Remission: A period during which cancer symptoms lessen or disappear, although the disease may not be completely cured.
  • Adverse Events: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Overall Survival: The length of time from either the date of diagnosis or the start of treatment that patients are still alive.

References

  1. http://clinicaltrials.eu/trial/long-term-safety-study-of-crispr-car-t-cell-therapy-for-patients-with-blood-and-solid-cancers/